Area of research
Infectious Diseases · Oncology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, COVID-19 and healthcare impacts, and SARS-CoV-2 detection and testing.
Retrospective case–case study investigation of a significant increase in Cryptosporidium spp. in England and Wales, August to September 2023
Systematic review of social determinants of childhood immunisation in low- and middle-income countries and equity impact analysis of childhood vaccination coverage in Nigeria.
An outbreak of Shiga toxin-producing <i>Escherichia coli</i> (STEC) O157:H7 associated with contaminated lettuce and the cascading risks from climate change, the United Kingdom, August to September 2022.
Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
Childhood vaccination coverage by socioeconomic, geographic, maternal, child, and healthcare characteristics in Nigeria: equity impact analysis
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
T cell response to SARS-CoV-2 infection in humans: A systematic review
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses
T cell response to SARS-CoV-2 infection in humans: A systematic review.
Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England.
Antibodies to SARS-CoV-2 protect against re-infection during outbreaks in care homes, September and October 2020.
An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021.
Horses for courses? Assessing the potential value of a surrogate, point-of-care test for SARS-CoV-2 epidemic control.
Antibody response to SARS-CoV-2 infection in humans: A systematic review
Antibody response to SARS-CoV-2 infection in humans: A systematic review.
A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study
Horses for courses? Assessing the potential value of a surrogate, point‐of‐care test for SARS‐CoV‐2 epidemic control
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
The Association Between Smoking and Electronic Cigarette Use in a Cohort of Young People
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Leadership and management in UK medical school curricula